Provided by Tiger Trade Technology Pte. Ltd.

Royalty Pharma plc

57.16
-0.4700-0.82%
Post-market: 57.160.00000.00%19:30 EDT
Volume:2.23M
Turnover:127.83M
Market Cap:32.98B
PE:30.66
High:57.91
Open:57.64
Low:56.96
Close:57.63
52wk High:64.38
52wk Low:35.23
Shares:576.94M
Float Shares:392.53M
Volume Ratio:0.82
T/O Rate:0.57%
Dividend:0.91
Dividend Rate:1.59%
EPS(TTM):1.86
EPS(LYR):1.78
ROE:13.97%
ROA:5.09%
PB:4.83
PE(LYR):32.09

Loading ...

Royalty Pharma signs USD 1.8 billion revolving credit facility, refinancing 2021 loan agreement

Reuters
·
May 29

How Investors May Respond To Royalty Pharma (RPRX) Strong Q1 Royalties And Expanding Biotech Partnerships

Simply Wall St.
·
May 28

Royalty Pharma EVP Marshall Urist sells 13,684 shares for $721,846.84

Reuters
·
May 22

Royalty Pharma EVP Marshall Urist sells 13,684 shares for $726,150.99

Reuters
·
May 16

Royalty Pharma Director Gregory Norden sells 3,045 shares for $161,385

Reuters
·
May 16

Royalty Pharma to present at BofA Securities Healthcare Conference webcast

Reuters
·
May 08

Royalty Pharma Is Maintained at Buy by Citigroup

Dow Jones
·
May 08

Bank of America Securities Keeps Their Buy Rating on Royalty Pharma (RPRX)

TIPRANKS
·
May 07

Royalty Pharma price target raised to $66 from $50 at Citi

TIPRANKS
·
May 07

Royalty Pharma (RPRX) Gets a Buy from TD Cowen

TIPRANKS
·
May 07

Royalty Pharma Q1 Adj. EPS $1.30 Beats $1.21 Estimate, Sales $631.000M Miss $1.235B Estimate

Benzinga Earnings
·
May 06

Royalty Pharma Q1 Net Income, Revenue Rise

MT Newswires Live
·
May 06

Royalty Pharma Q1 adjusted EBITDA climbs 21% to $889 million; portfolio receipts rise 10% to $925 million

Reuters
·
May 06

Royalty Pharma - Raises FY2026 Portfolio Receipts Guidance to $3.325 Bln-$3.45 Bln

THOMSON REUTERS
·
May 06

Royalty Pharma Q1 Operating Income USD 563 Million

THOMSON REUTERS
·
May 06

Royalty Pharma Q1 Net Income USD 468 Million

THOMSON REUTERS
·
May 06

Royalty Pharma CFO Terrance Coyne disposes of 34,791 shares worth $1.73 million

Reuters
·
May 01

Earning Preview: Royalty Pharma plc Q1 revenue is expected to increase by 64.58%, and institutional views are constructive

Earnings Agent
·
Apr 29

Royalty Pharma Is Maintained at Buy by UBS

Dow Jones
·
Apr 22

UBS Adjusts Royalty Pharma Price Target to $57 From $51, Maintains Buy Rating

MT Newswires Live
·
Apr 21